NATICK, Mass. and CHICAGO, April 1, 2008 /PRNewswire-FirstCall/ --
Boston Scientific Corporation (NYSE: BSX) today welcomed favorable outcomes
of one- year data from the Company's TAXUS IV and V randomized clinical
trials in patients who received the TAXUS(R) Express(TM) Paclitaxel-Eluting
Coronary Stent System compared to patients who received bare-metal stents
(BMS). These results add to the growing body of evidence that
paclitaxel-eluting stents are clinically beneficial over BMS even in the
treatment of large vessels (greater than 3.5 mm), which typically have
reduced restenosis risk compared to smaller diameter vessels. David A. Cox,
M.D., FACC, presented the TAXUS IV and V results at the SCAI Annual
Scientific Sessions in Partnership with the ACC/i2 Summit in Chicago.

In an analysis of TAXUS IV and V one-year clinical events, Dr. Cox
reported that patients treated with the TAXUS Stent had significant
reductions in one-year revascularization rates in both large and small
diameter vessels compared to BMS. Although the absolute magnitude of the
efficacy benefit was reduced in large diameter vessels, the relative
reduction compared to BMS was maintained.

Results include outcomes from 2,458 patients divided into three groups
according to maximal device diameter (defined as the diameter of the
largest final stent or post-dilatation balloon utilized): <3.5 mm (n=1,528
patients), >/=3.5mm-<4.0mm (n=655), and >/=4.0mm (n=275). Compared to BMS,
patients treated with the TAXUS Stent had lower rates of target lesion
revascularization (TLR) at all device diameters: 9.7% vs. 20.4% (p<0.001)
for <3.5mm, 4.5% vs. 13.5% (p<0.001) for >/=3.5mm-<4.0mm, and 1.6% vs. 6.5%
(p<0.05) for >4.0mm. These rates correspond to reductions of 52.5% for the
<3.5mm group, 66.7% for the >/=3.5mm-<4.0mm group, and 75.4% for the
>/=4.0mm group, suggesting that although the magnitude of the absolute TLR
difference between TAXUS and BMS was reduced in larger diameter vessels,
the relative reduction was actually greater. Significant reductions in
target vessel revascularization (TVR) and MACE were also reported in both
small and larger diameter vessels. There were no statistically significant
differences in the incidences of cardiac death, myocardial infarction or
stent thrombosis.

"The risk for restenosis with BMS is generally decreased in large
vessels, prompting some interventional cardiologists to choose BMS over DES
in vessels larger than 3.5mm. However, since larger vessels also surround
significant amounts of heart muscle tissue, even small differences in
clinical events between BMS and DES may be clinically relevant," said Dr.
Cox. "Our analyses of TAXUS IV and V data clearly add to the growing body
of evidence that DES still appear clinically beneficial over BMS in the
treatment of large vessels."

The safety and effectiveness of the TAXUS Express Stent has not been
established in lesions with reference vessel diameters >3.75mm.

Boston Scientific is a worldwide developer, manufacturer and marketer
of medical devices whose products are used in a broad range of
interventional medical specialties. For more information, please visit:
http://www.bostonscientific.com.

Cautionary Statement Regarding Forward Looking Statements

This press release contains forward-looking statements within the
meaning of Section 21E of the Securities Exchange Act of 1934.
Forward-looking statements may be identified by words like "anticipate,"
"expect," "project," "believe," "plan," "estimate," "intend" and similar
words. These forward- looking statements are based on our beliefs,
assumptions and estimates using information available to us at the time and
are not intended to be guarantees of future events or performance. These
forward-looking statements include, among other things, statements
regarding clinical trials, regulatory approvals, competitive offerings,
product performance and our market position. If our underlying assumptions
turn out to be incorrect, or if certain risks or uncertainties materialize,
actual results could vary materially from the expectations and projections
expressed or implied by our forward-looking statements. These factors, in
some cases, have affected and in the future (together with other factors)
could affect our ability to implement our business strategy and may cause
actual results to differ materially from those contemplated by the
statements expressed in this press release. As a result, readers are
cautioned not to place undue reliance on any of our forward- looking
statements.

Factors that may cause such differences include, among other things:
future economic, competitive, reimbursement and regulatory conditions; new
product introductions; demographic trends; intellectual property;
litigation; financial market conditions; and, future business decisions
made by us and our competitors. All of these factors are difficult or
impossible to predict accurately and many of them are beyond our control.
For a further list and description of these and other important risks and
uncertainties that may affect our future operations, see Part I, Item 1A --
Risk Factors in our most recent Annual Report on Form 10-K filed with the
Securities and Exchange Commission, which we may update in Part II, Item 1A
-- Risk Factors in Quarterly Reports on Form 10-Q we have filed or will
file thereafter. We disclaim any intention or obligation to publicly update
or revise any forward- looking statements to reflect any change in our
expectations or in events, conditions, or circumstances on which those
expectations may be based, or that may affect the likelihood that actual
results will differ from those contained in the forward-looking statements.
This cautionary statement is applicable to all forward-looking statements
contained in this document.

(Date:12/8/2016)... KEY FINDINGS The global medical lifting sling ... for growth of the medical lifting sling market are ... high recovery cost of injuries and government initiatives to ... refers to an assistive device that helps caregiver transfer ... the lift and hold the patient. It is important ...

(Date:12/8/2016)... 8, 2016 Eli Lilly and Company (NYSE: ... phase 3 EXPEDITION3 trial at the 9 th ... disclosed, solanezumab did not meet the primary endpoint in ... in people with mild dementia due to Alzheimer,s disease ... solanezumab for the treatment of mild dementia due to ...

(Date:12/8/2016)... ... ... With the increasing demand for dental implants, the National Association of Dental Laboratories ... and patients about the safety issues related to dental restorations. According to the American ... projected to reach $6.4 billion in 2018 with more than 30 million Americans missing ...

(Date:12/8/2016)... ... December 08, 2016 , ... SunView Software ... and employees that are both engaging and easy to use. Coming off the ... software company revealed today its plans to roll out new AI-powered self-service enhancements ...

(Date:12/8/2016)... ... December 08, 2016 , ... STATEN ISLAND, N.Y., ... for adherence to the highest standards of trauma, maternity, cancer and chronic obstructive ... president and CEO, Dr. Daniel Messina. , Among the recognitions, the American College ...